Medicus Pharma gets FDA feedback and IRB nod for smaller Phase 2 trial
Tweet Send to a Friend
Medicus Pharma Ltd. (NASDAQ: MDCX) said it received written feedback from the U.S. Food and Drug Administration and central Institutional ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


